Annovis Bio (ANVS) News Today $1.40 -0.19 (-11.64%) Closing price 04/3/2025 03:58 PM EasternExtended Trading$1.41 +0.00 (+0.36%) As of 04/3/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Annovis Bio (ANVS) to Release Quarterly Earnings on FridayApril 2 at 1:06 AM | americanbankingnews.comAnnovis Bio Receives Non-Compliance Notice from NYSEMarch 29, 2025 | msn.comAnnovis Bio Inc.: Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSEMarch 29, 2025 | finanznachrichten.deAnnovis Bio receives noncompliance notification from NYSEMarch 28, 2025 | markets.businessinsider.comAnnovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025March 27, 2025 | msn.comAnnovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSEMarch 27, 2025 | globenewswire.comAnnovis Bio, Inc. (NYSE:ANVS) Receives Average Rating of "Buy" from BrokeragesMarch 27, 2025 | americanbankingnews.comAnnovis to Attend AD/PD™ 2025 with Extensive Scientific ProgramMarch 25, 2025 | finance.yahoo.comAnnovis to Attend AD/PD™ 2025 with Extensive Scientific ProgramMarch 25, 2025 | globenewswire.comAnnovis Bio Reports Progress in Clinical Trials and Improved Financial PositionMarch 24, 2025 | msn.comAnnovis Bio Inc.: Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 22, 2025 | finanznachrichten.deAnnovis Bio reports Q4 EPS (43c) vs. ($2.24) last yearMarch 22, 2025 | markets.businessinsider.comAnnovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 21, 2025 | globenewswire.comAnnovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development SummitMarch 13, 2025 | msn.comAnnovis Joins Experts at Drug Development Summit to Redefine Parkinson's TreatmentMarch 11, 2025 | globenewswire.comAnnovis Bio-Aktie fällt auf 52-Wochen-Tief von 2,42 US-DollarFebruary 20, 2025 | de.investing.comAnnovis Bio to Host Patient-Centered Webcast on Key Clinical DevelopmentsFebruary 20, 2025 | msn.comAnnovis to Host Patients' Live Forum on February 27, 2025February 19, 2025 | globenewswire.comAnnovis Bio-Aktie fällt auf 52-Wochen-Tief bei 2,59 US-DollarFebruary 11, 2025 | de.investing.comAnnovis Bio stock hits 52-week low at $2.59 amid sharp declineFebruary 11, 2025 | msn.comAnnovis Bio downgraded to Hold from Buy at D. Boral CapitalFebruary 11, 2025 | markets.businessinsider.comD. Boral Capital Downgrades Annovis Bio (ANVS)February 11, 2025 | msn.comAnnovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFebruary 7, 2025 | globenewswire.comAnnovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s DiseaseFebruary 6, 2025 | markets.businessinsider.comAnnovis Bio announces first patients entered Phase 3 study of buntanetapFebruary 6, 2025 | markets.businessinsider.comAnnovis Bio (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug DevelopmentFebruary 6, 2025 | theglobeandmail.comAnnovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s ResearchFebruary 6, 2025 | msn.comAnnovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's DiseaseFebruary 5, 2025 | globenewswire.comAnnovis Bio, Inc. Announces Closing of $21 Million Public OfferingFebruary 4, 2025 | financialpost.comAnnovis Bio, Inc. Announces Closing of $21 Million Public OfferingFebruary 4, 2025 | globenewswire.comAnnovis Bio Prices Offering Of 5.25 Mln Shares At $4/Share, Stock Falls In Pre-MarketFebruary 3, 2025 | markets.businessinsider.comAnnovis Bio falls -25.6%February 3, 2025 | markets.businessinsider.comAnnovis Bio stock dips after pricing $21M securities offeringFebruary 3, 2025 | msn.comAnnovis Bio stock hits 52-week low at $4.05 amid market challengesFebruary 3, 2025 | msn.comAnnovis Bio, Inc. Announces Pricing of $21 Million Public OfferingFebruary 3, 2025 | financialpost.comAnnovis Bio announces pricing of $21M offering of stock, warrantsFebruary 3, 2025 | markets.businessinsider.comAnnovis Bio, Inc. Announces Pricing of $21 Million Public OfferingFebruary 3, 2025 | globenewswire.comAnnovis Bio Announces Public Offering of Common Stock and WarrantsFebruary 2, 2025 | msn.comAnnovis Bio, Inc. Announces Proposed Public OfferingJanuary 31, 2025 | financialpost.comAnnovis Bio, Inc. Announces Proposed Public OfferingJanuary 31, 2025 | financialpost.comAnnovis Bio, Inc. Announces Proposed Public OfferingJanuary 31, 2025 | globenewswire.comAnnovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Merit Financial Group LLCMerit Financial Group LLC lifted its stake in shares of Annovis Bio, Inc. (NYSE:ANVS - Free Report) by 269.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,516 shares of the company's stock after buying an additional 71,81January 24, 2025 | marketbeat.comAnnovis Bio Secures U.S. Patent for Neuroprotective Drug BuntanetapJanuary 17, 2025 | msn.comAnnovis Bio granted U.S. patent covering buntanetapJanuary 14, 2025 | markets.businessinsider.comAnnovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global ProtectionJanuary 14, 2025 | globenewswire.comAnnovis Bio, Inc. (NYSE:ANVS) Given Average Rating of "Buy" by AnalystsShares of Annovis Bio, Inc. (NYSE:ANVS - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buyJanuary 11, 2025 | marketbeat.comAnnovis Bio: Strategic Advancements and Phase 3 Trial Acceleration Justify Buy RatingJanuary 8, 2025 | markets.businessinsider.comFDA Accepts Revised Protocol for Annovis Bio’s Phase 3 Alzheimer’s StudyJanuary 8, 2025 | msn.comAnnovis Bio announces FDA acceptance of protocol for Phase 3 AD studyJanuary 8, 2025 | markets.businessinsider.comFDA genehmigt überarbeitetes Protokoll für Annovis Bios Phase-3-Studie zur Alzheimer-KrankheitJanuary 7, 2025 | de.investing.com Remove Ads Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address ANVS Media Mentions By Week ANVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANVS News Sentiment▼0.110.60▲Average Medical News Sentiment ANVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANVS Articles This Week▼44▲ANVS Articles Average Week Remove Ads Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Caribou Biosciences News Today Silence Therapeutics News Today Exicure News Today Zura Bio News Today Kyverna Therapeutics News Today Vigil Neuroscience News Today Pliant Therapeutics News Today Climb Bio News Today Ventyx Biosciences News Today MacroGenics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANVS) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
